Literature DB >> 3129204

Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product.

S Ozawa1, Y Sugiyama, Y Mitsuhashi, T Kobayashi, M Inaba.   

Abstract

Based on a pharmacokinetic model proposed by Jusko, which assumes that the cell killing action of cell cycle phase-non-specific agents occurs as a bimolecular reaction depending on drug concentration and cell density, we derived a cell kill kinetic equation for these drugs, including the decomposition constant in culture medium. This equation revealed that the cell killing activity of these drugs depends on the value of concentration x exposure time or the area under the drug concentration--time curve (AUC). It was also clarified that the curves for concentration--exposure time necessary for 90% cell kill on a log scale simulated on the basis of the equation differ according as whether drugs are stable or unstable in the culture medium, being expected to be linear with a slope of -1 in the former case, and to take the form of an asymptotic curve in the latter. For three cell cycle phase-non-specific agents, mitomycin C (MMC), 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)3-nitrosoure a hydro-chloride (ACNU), and nitrogen mustard (HN2), we assessed the concentrations necessary for 90% cell kill (IC90) with various exposure times and the degradation rate constants under the culture conditions used. MMC was quite stable during the incubation, while ACNU and HN2 were unstable. When IC90's and exposure times were plotted on the above-mentioned graph, a linear relationship with a slope of -1 was seen for MMC, while for ACNU and HN2 the anticipated asymptotic curves resulted. We also ascertained that the decomposition constants for ACNU and HN2 expected on the basis of these curves showed a good agreement with the corresponding experimentally observed values. These results indicate that the cell killing action of cell cycle phase-non-specific drugs can be well described by a pharmacodynamic model and equation employing their decomposition constants and are dependent on the concentration-time product.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129204     DOI: 10.1007/bf00262767

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  Dosage regimen design for pharmaceutical studies conducted in animals.

Authors:  J Mordenti
Journal:  J Pharm Sci       Date:  1986-09       Impact factor: 3.534

2.  Clinical anticancer pharmacology: some pharmacokinetic considerations.

Authors:  V A Levin
Journal:  Cancer Treat Rev       Date:  1986-06       Impact factor: 12.111

3.  Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.

Authors:  G P Wheeler; B J Bowdon; J A Grimsley; H H Lloyd
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

4.  Quantitative clonal growth of mammalian cells: its application for quantitative study of cytocidal action of Mitomycin-C.

Authors:  M Shimoyama; K Kimura
Journal:  Gan       Date:  1972-12

5.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

Review 6.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Anticancer drugs: effect on the cloning of Raji lymphoma cells in soft agar.

Authors:  P C Wu; R F Ozols; M Hatanaka; C W Boone
Journal:  J Natl Cancer Inst       Date:  1982-01       Impact factor: 13.506

8.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

9.  Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro.

Authors:  H T Rupniak; R D Whelan; B T Hill
Journal:  Int J Cancer       Date:  1983-07-15       Impact factor: 7.396

10.  Metabolic activation of mitomycin C by liver microsomes and nuclei.

Authors:  K A Kennedy; S G Sligar; L Polomski; A C Sartorelli
Journal:  Biochem Pharmacol       Date:  1982-06-01       Impact factor: 5.858

View more
  29 in total

1.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

2.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up.

Authors:  Y Mitsuhashi; Y Sugiyama; S Ozawa; T Nitanai; K Sasahara; K Nakamura; M Tanaka; T Nishimura; M Inaba; T Kobayashi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma.

Authors:  M Kochii; I Kitamura; T Goto; T Nishi; H Takeshima; Y Saito; K Yamamoto; T Kimura; T Kino; K Tada; S Shiraishi; S Uemura; T Iwasaki; J Kuratsu; Y Ushio
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

5.  Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

Authors:  A Haldane; G J Finlay; J B Gavin; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in dogs.

Authors:  M Kochi; S Takaki; J Kuratsu; H Seto; I Kitamura; Y Ushio
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  The effect of locally implanted complexes of adriamycin-hydroxyapatite complexes on tumor--study of a new alternative treatment for hepatic cancer.

Authors:  Q Xia; H Nie; D Chen; J Chen; Y Tian; J Zhang
Journal:  J Tongji Med Univ       Date:  1999

8.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

9.  Cisplatin-induced hair cell loss in zebrafish (Danio rerio) lateral line.

Authors:  Henry C Ou; David W Raible; Edwin W Rubel
Journal:  Hear Res       Date:  2007-07-19       Impact factor: 3.208

10.  Kinetic analysis of the in vitro cell-killing action of neocarzinostatin.

Authors:  S Ozawa; M Inaba
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.